SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-23-004783
Filing Date
2023-04-17
Accepted
2023-04-17 16:26:40
Documents
12
Period of Report
2023-04-12
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_041223.htm   iXBRL 8-K 31543
  Complete submission text file 0001387131-23-004783.txt   207310

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20230412.xsd EX-101.SCH 3266
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20230412_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20230412_pre.xml EX-101.PRE 22385
6 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_041223_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 23824254
SIC: 2834 Pharmaceutical Preparations